Sex-dependent role of glucocorticoids and androgens in the pathophysiology of human obesity

International Journal of Obesity

Volumn 32, Issue 12, 2008, Pages 1764-1779

  Pasquali, R ^a   Vicennati, V ^a   Gambineri, A ^a   Pagotto, U ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Androgens; Cortisol; Females; Males

Indexed keywords

ANDROGEN; GLUCOCORTICOID; HYDROCORTISONE; TESTOSTERONE;

ABDOMINAL OBESITY; ACUTE STRESS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CHRONIC STRESS; COMORBIDITY; DISEASE PREDISPOSITION; HORMONAL REGULATION; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; REVIEW; SEX DIFFERENCE;

ANDROGENS; ANIMALS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOCORTICOIDS; GONADAL STEROID HORMONES; HUMANS; HYDROCORTISONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; OBESITY; PITUITARY-ADRENAL SYSTEM; RATS; SEX FACTORS; STRESS, PHYSIOLOGICAL;

EID: 57749184775     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2008.129     Document Type: Review

References (139)

1. Haslan DW, James WPT. Obesity. Lancet 2005; 366: 1197-1209.
2. Roth J, Quiang X, Marban SL, Redelt H, Lowell BC. The obesity pandemic: where have we been and where are we going? Obesity Res 2004; (12 Suppl): 88S-101S.
3. Rosmond R. Role of stress in the pathogenesis of the metabolic syndrome. Psychoneuroendocrinology 2005; 30: 1-10.
4. Dandona P, Aljada A, Chandhuri A, Mohanty P, Garg R. Metabolic syndrome. A comprehensive perspective based on interaction between obesity, diabetes, and inflammation. Circulation 2005; 111: 1448-1454.
5. Dandona P, Aljada A, Mohanty P. The anti-inflammatory and potential anti-atherogenic effect of insulin: a new paradigm. Diabetologia 2002; 45: 924-930.
6. Pinkney JH, Kopelman PG. Endocrine determinants of obesity. In: GA Bray and C Bouchard (eds). Handbook of Obesity. Etiology and pathophysiology 2nd edn, Marcel Dekker Inc.: New York, 2004; 655-670.
7. Pasquali R. Endocrine determinants of fat distribution. In: GA Bray and C Bouchard (eds). Handbook of Obesity. Etiology and pathophysiology 2nd edn. Marcel Dekker Inc.: New York, 2004; 671-692.
8. Pasquali R, Vicennati V. Obesity and hormonal abnormalities. In: P. Bjorntorp (ed). International Textbook of Obesity. John Wiley & Sons, Ltd: Chicester, UK, 2001. pp. 225-239.
9. Pasquali R. Obesity and androgens: facts and perspectives. Fertil Steril 2006; 85: 1310-1340.
10. Samojlik E, Kirschner MA, Silber D, Schneider G, Ertel NH. Elevated production and metabolic clearance rates of androgens in morbidly obese women. J Clin Endocrinol Metab 1984; 59: 949-954.
11. Kirschner MA, Samojlik E, Drejka M, Szmal E, Schneider G, Ertel N. Androgen-estrogen metabolism in women with upper body versus lower body obesity. J Clin Endocrinol Metab 1990; 70: 473-479.
12. Zumoff B, Strain GW, Miller LK, Rosner W, Senie R, Seres DS et al. Plasma free and non-sex-hormone-binding-globulin-bound testosterone are decreased in obese men in proportion to their degree of obesity. J Clin Endocrinol Metab 1990; 71: 929-931.
13. Björntorp P. Do stress reactions cause abdominal obesity and comorbidities? Obes Rev 2001; 2: 73-86.
14. Pasquali R, Vicennati V, Cacciari M, Pagotto U. The hypothalamic- pituitary-adrenal axis activity in obesity and the metabolic syndrome. Ann NY Acad Sci 2006; 1083: 111-128.
15. Viau V. Functional cross-talk between the hypothalamic-pituitary-gonadal and -adrenal axes. J Neuroendocrinol 2002; 14: 506-513.
16. Vicennati V, Ceroni L, Genghini S, Patton L, Pagotto U, Pasquali R. Sex difference in the relationship between the hypothalamic-pituitary-adrenal axis and sex hormones in obesity. Obes Res 2006; 14: 235-243.
17. Roca CA, Schmidt PJ, Deuster PA Altemus M, Putnam K, Ghrousos GP et al. Sex-related differences in stimulated axis during induced gonadal suppression. J Clin Endocrinol Metab 2005; 90: 4224-4231.
18. Pasquali R, Vicennati V. The abdominal obesity phenotype and insulin resistance are associated with abnormalities of the hypothalamic-pituitary- adrenal axis in humans. Horm Metab Res 2000; 32: 521-525.
19. Tomlinson JW, Walker EA, Bujalska IJ, Draper N, Lavery GG, Cooper MS et al. 11β-hydroxysteroid dehydrogenase type 1: a tissue specific regulation of glucorticoid response. Endocr Rev 2004; 25: 831-866.
20. Walker BR. Glucocorticoids and cardiovascular disease. Eur J Endocrinol 2007; 157: 545-559.
21. Buckingham JC. Glucocorticoids: exemplars of multi-tasking. Br J Pharmacol 2006; 147: S258-S268.
22. Dallman MF, La Fleaur SE, Pecorao NC, Gomez F, Houshyar H et al. Minireview: Glucorticoids - food intake, abdominal obesity, and wealthy nations in 2004. Endocrinology 2004; 145: 2633-2638.
23. Federman DD. The biology of sex differences. N Engl J Med 2006; 354: 1507-1514.
24. James WPT, Rigby N, Leach R. The obesity epidemic, metabolic syndrome and future preventive strategies. Eur J Cardiovasc Prev Rehabil 2004; 11: 3-8.
25. National Health and Nutrition Examination Survey. Healthy weight, overweight, and obesity among US adults (website of the Centers for Disease Control and Prevention) Available www.Cdc.gov/nchs/data/nhanes/databrief/ adultweight.pdf (accessed 2006 Dec 19).
26. Tremblay MS, Pérez CE, Ardern CI, Bryan SN, Katzmarzyk PT. Obesity, overweight and ethnicity. Health Rep 2005; 16: 23-34.
27. Pilote L, Dasgupta K, Guru V, Humphries KH, McGrath J, Norris C et al. A comprehensive review of sex specific issues related to cardiovascular disease. CMAJ 2007; 176 (6 Suppl): S1-S44.
28. International Diabetes Federation: the IDF worldwide definition of the metabolic syndrome. Available from http://www.cdc.gov/nchs/about/major/nhanes/ nhanes/99-02.htm Accessed 18 May 2005.
29. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365: 1415-1428.
30. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
31. Ford ES. Prevalence of the metabolic syndrome in US population. Endocrinol Metab Clin N Am 2004; 33: 333-350.
32. Resnick HE. Strong Heart Study Investigators: metabolic syndrome in American Indians. Diabetes Care 2002; 25: 1246-1247.
33. American College of Endocrinology Task Force on the Insulin Resistance Syndrome. American College of Endocrinology Position Statement on the insulin resistance syndrome. Endocr Pract 2002; 9: 236-252.
34. Alberti K, Zimmet P. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Report of a WHO consultation. Diab Med 1998; 15: 539-553.
35. World Heath Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Geneva (Switzerland): Department of Noncommunicable Disease Surveillance 1999.
36. Despres JP. Abdominal obesity as important component of insulin resistance syndrome. Nutrition 1993; 9: 452-459.
37. Bjorntorp P, Rosmond R. The metabolic syndrome - a neuroendocrine disorder. Br J Nutr 2000; 83 (Suppl 1): S49-S57.
38. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 2000; 21: 697-738.
39. Regitz-Zagrosek V, Lehmthul E, Weickert MO. Gender differences in the metabolic syndrome and their role for cardiovascular disease. Clin Res Cardiol 2006; 95: 136-147.
40. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-3421.
41. Carr DB, Utzschneider KM, Hull RL, Kodama K, Retzlaff BM, Brunzell JD et al. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes 2004; 53: 2087-2094.
42. Comaschi M, Coscelli C, Cucinotta D, Malini P, Manzato E, Nicolucci A, SFIDA Study Group-Italian Association of Diabetologists (AMD). Cardiovascular risk factors and metabolic control in type 2 diabetic subjects attending outpatient clinics in Italy: the SFIDA (survey of risk factors in Italian diabetic subjects by AMD) study. Nutr Metab Cardiovasc Dis 2005; 15: 204-211.
43. Mannucci E, Alegiani SS, Monami M, Sarli E, Avogaro A, DAI (Diabetes Informatics) Study Group. Indexes of abdominal adiposity in patients with type 2 diabetes. J Endocrinol Invest 2004; 27: 535-540.
44. Marchesini G, Forlani G, Cerrelli F, Manini R, Natale S, Baraldi L et al. WHO and ATPIII proposals for the definition of the metabolic syndrome in patients with Type 2 diabetes. Diabet Med 2004; 21: 383-387.
45. Sundstrom J, Riserus U, Byberg L, Zethelius B, Lithell H, Lind L. Clinical values of the metabolic syndrome for long term prediction of total and cardiovascular mortality: prospective, population based cohort study. BMJ 2006; 332: 878-882.
46. Kanaya AM, Vittinghoff E, Shlipack MG, Rosnick HE, Visser M, Grady D et al. Association of central obesity with mortality in postmenopausal women with coronary artery disease. Am J Epidemiol 2003; 158: 1161-1170.
47. Chan JM, Rimm EB, Colditz GA, Stampfer MJ, Willett WC. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care 1994; 17: 961-969.
48. Colditz GA, Willett WC, Rotnitzky A, Manson JE.Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 1995; 122: 481-486.
49. Bjorntorp P. The regulation of adipose tissue distribution in humans. Int J Obes 1996; 20: 291-302.
50. Bjorntorp P, Rosmond R. Neuroendocrine abnormalities in visceral obesity. Int J Obes 2000; 24: 580-585.
51. Rebuffé-Scrive M, Lundholm K, Bjorntorp P. Glucocorticoid hormone binding to human adipose tissue. Eur J Clin Invest 1985; 15: 267-271.
52. Sandeep TC, Walker BR. Pathophysiology of modulation of local glucocorticoid levels by11 β-hydroxysteroid dehydrogenase. Trends Endocrinol Metab 2001; 12: 446-453.
53. Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR et al. A transgenic model of visceral obesity and the metabolic syndrome. Science 2001; 294: 2166-2170.
54. Kotelevtsev Y, Holmes MC, Burchell A, Houston PM, Schmoll D, Jamieson P et al. 11b-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc Natl Acad Sci 1997; 94: 14924-14929.
55. Morton NM, Holmes MC, Fievet C, Staels B, Tailleux A, Mullins JJ et al. Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11b-hydroxy- steroid dehydrogenase type 1 null mice. J Biol Chem 2001; 276: 41293-41300.
56. Von Shoultz B, Carlstrom K. On the regulation of sex-hormone-binding globulin. A challenge of old dogma and outlines of an alternative mechanism. J Steroid Biochem 1989; 32: 327-334.
57. Tchernof A, Despres JP. Sex steroid hormones, sex hormone-binding globulin, and obesity in men and women. Horm Metab Res 2000; 32: 526-536.
58. Kurtz BR, Givens JR, Komindr S, Stevens MD, Karas JG, Bittle JB et al. Maintenance of normal circulating levels of Δ4-androstenedine and dehydroepiandrosterone in simple obesity despite increased metabolic clearance rates: evidence for a servo-control mechanism. J Clin Endocrinol Metab 1987; 64: 1261-1267.
59. Pasquali R, Casimirri F, Platè L, Capelli M. Characterization of obese women with reduced sex hormone-binding globulin concentrations. Horm Metab Res 1990; 22: 303-306.
60. Evans DJ, Hoffmann RG, Kalkhoff RK, Kissebah AH. Relationship of androgenic activity to body fat topography, fat cell morphology and metabolic aberrations in premenopausal women. J Clin Endocrinol Metab 1983; 57: 304-310.
61. Strain GW, Zumoff B, Kream J, Strain JJ, Deucher R, Rosenfeld RS et al. Mild hypogonadotropic hypogonadism in obese men. Metabolism 1982; 31: 871-875.
62. Tchernof A, Despres JP, Belanger A, Dupont A, Prud'homme D, Moorjani S et al. Reduced testosterone and adrenal C19 steroid levels in obese men. Metabolism 1995; 44: 513-519.
63. Giagulli VA, Giorgino R, Vermeulen A. Origin and significance of plasma androsterone glucuronide levels: a parameter of adrenal androgen secretion and hepatic 5 alpha-reductase activity. J Clin Endocrinol Metab 1993; 76: 918-923.
64. Khaw KT, Barrett-Connor E. Lower endogenous androgens predict central adiposity in men. Ann Epidemiol 1992; 2: 675-682.
65. Pasquali R, Casimirri F, Cantobelli S, Melchionda N, Morselli Labate AM, Fabbri R et al. Effect of obesity and body fat distribution on sex hormones and insulin in men. Metabolism 1991; 40: 101-104.
66. Leenen R, van der Koy K, Seidell JC, Deurenberg P, Kopperschaar HPF. Visceral fat accumulation in relation to sex hormones in obese men and women undergoing weight loss therapy. J Clin Endocrinol Metab 1994; 98: 1515-1520.
67. Selye H. Syndrome produced by diverse nocuous agents. Nature 1936; 1: 38-42.
68. Plotsky PM, Cunningham ET, Widmaier EP. Catecholaminergic modulation of corticotropin-releasing factor and adrenocorticotropin secretion. Endocr Rev 1989; 10: 437-445.
69. Hjemdahl P. Stress and the metabolic syndrome. An interesting but enigmating association. Circulation 2002; 106: 2634-2636.
70. McEwen BS. Protective and damaging effects of stress mediators. N Engl J Med 1998; 338: 171-179.
71. Shively C, Clarkson T. Regional obesity and coronary atherosclerosis in females: a non-human primate model. Acta Med Scand 1989; 723: 71-78.
72. Bjorntorp P. Centralization of body fat. In: Bjorntorp P (ed). International Textbook of obesity. John Wiley & Sons: Chichester, UK, 2001; 213-224.
73. Chrousos GP. Editorial: a healthy body in a healthy mind and vice versa. The damaging power of 'uncontrollable' stress. J Clin Endocrinol Metab 1998; 83: 1842-1845.
74. Björntorp P. Visceral obesity: a 'Civilization Syndrome'. Obes Res 1993; 1: 206-222.
75. Rosmond R, Lapidus L, Björntorp P. The influence of occupational and social factors on obesity and body fat distribution in middle aged-men. Int J Obes 1996; 20: 599-607.
76. Rosmond R, Lapidus L, Marin P, Björntorp P. Mental distress, obesity and body fat distribution in middle-aged women. Obes Res 1996; 4: 245-252.
77. Seeman TE, McEwen BS, Rowe JW, Singer BH. Allostatic load as a marker of cumulative biological risk: MacArthur studies of successful aging. Proc Natl Acad Sci USA 2001; 98: 4770-4775.
78. Gruenewald TL, Seeman TE, Ryff CD, Karlamangla AS, Singer BH. Combinations of biomarkers predictive of later life mortality. Proc Natl Acad Sci USA 2006; 103: 14158-14163.
79. Viau V, Meaney MJ. The inhibitory effect of testosterone on hypothalamic-pituitary-adrenal responses to stress is mediated by the medial preoptic area. J Neurosci 1996; 16: 1866-1876.
80. Barat P, Livingstone DE, Elferink CM, McDonnell CR, Walker BR, Andrew R. Effects of gonadectomy on glucocorticoid metabolism in obese Zucker rats. Endocrinology 2007; 148: 4836-4843.
81. Tilbrook AJ, Turner AI, Clarke IJ. Effects of stress on reproduction in non-rodent mammals: the role of glucocorticoids and sex differences. Rev Reprod 2000; 5: 105-113.
82. Rivier C, Rivest S. Effect of stress on the activity of the hypothalamic-pituitary-gonadal axis: peripheral and central mechanisms. Biol Reprod 1991; 45: 523-532.
83. Gallucci WT, Baum A, Laue L, Rabin DS, Chrousos GP, Gold PW et al. Sex difference in sensitivity of the hypothalamic-pituitary-adrenal axis. Health Psychol 1993; 12: 420-425.
84. Streeten DH, Anderson Jr GH, Dalakos TG, Seeley D, Mallov JS, Eusebio R et al. Normal and abnormal function of the hypothalamic-pituitary- adrenocortical axis in man. Endocr Rev 1984; 5: 371-394.
85. Pasquali R, Gagliardi L, Vicennati V, Gambineri A, Colitta D, Ceroni L et al. ACTH and cortisol response to combined corticotropin releasing hormone-arginine vasopressin stimulation in obese males and its relationship to body weight, fat distribution and parameters of the metabolic syndrome. Int J Obes Relat Metab Disord 1999; 23: 419-424.
86. Wiedemann K, Holsboer F. The effect of repeated human corticotropin-releasing hormone administration on dexamethasone-suppressed pituitary-adrenocortical activity in healthy subjects. Biol Psychiatry 1997; 42: 882-888.
87. Pasquali R, Cantobelli S, Casimirri F, Capelli M, Bortoluzzi L, Flamia R et al. The hypothalamic-pituitary-adrenal axis in obese women with different patterns of body fat distribution. J Clin Endocrinol Metab 1993; 77: 341-346.
88. Rosmond R, Dallman MF, Bjorntorp P. Stress-related cortisol secretion in men: relationships with abdominal obesity and endocrine, metabolic and hemodynamic abnormalities. J Clin Endocrinol Metab 1998; 83: 1853-1859.
89. Lesniewska B, Miskowiak B, Nowak M, Malendowicz LK. Sex differences in adrenocortical structure and function. XXVII. The effect of ether stress on ACTH and corticosterone in intact, gonadectomized, and testosterone- or estradiol-replaced rats. Res Exp Med (Berl) 1990; 190: 95-103.
90. Norman RL, Smith CJ, Pappas JD, Hall J. Exposure to ovarian steroids elicits a female pattern of cortisol levels in castrated male macaques. Steroids 1992; 57: 37-43.
91. Kirschbaum C, Schommer N, Federenko I, Gaab J, Neumann O, Oellers M et al. Short-term estradiol treatment enhances pituitary-adrenal axis and sympathetic responses to psychosocial stress in healthy young men. J Clin Endocrinol Metab 1996; 81: 3639-3643.
92. Chrousos G, Gold PW. The concept of stress and stress system disorders. JAMA 1992; 267: 1244-1252.
93. Olsen DH, Ferin M. Corticotropin-releasing hormone inhibits gonadotropin secretion in ovariectomized rhesus monkey. J Clin Endocrinol Metab 1987; 65: 262-267.
94. Poretsky L, Cataldo NA, Rosenwaks Z, Giudice LC. The insulin-related ovarian regulatory system in health and disease. Endocr Rev 1999; 20: 535-582.
95. Vierhapper H, Nowotny P, Waldhausl W. Production rates of testosterone in patients with Cushing's syndrome. Metabolism 2000; 49: 229-231.
96. Lado-Abeal J, Rodriguez-Arnao J, Newell-Price JD, Perry LA, Grossman AB, Besser GM et al. Menstrual abnormalities in women with Cushing's disease are correlated with hypercortisolemia rather than raised circulating androgen levels. J Clin Endocrinol Metab 1998; 83: 3083-3088.
97. Kahn R, Ferrranini E, Buse J, Stern M. The metabolic syndrome: time for a critical reappraisal. Joint statement from the American Diabetes Association and the European Association for the study of Diabetes. Diabetes Care 2005; 28: 2289-2304.
98. Reaven GM. Insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.
99. Phillips DI, Barker DJ, Fall CH, Seckl JR, Whorwood CB, Wood PJ et al. Elevated plasma cortisol concentrations: a link between low birth weight and the insulin resistance syndrome? J Clin Endocrinol Metab 1998; 83: 757-760.
100. Dinneen S, Alzaid A, Miles J, Rizza R. Metabolic effects of the nocturnal rise in cortisol on carbohydrate metabolism in normal humans. J Clin Invest 1993; 92: 2283-2290.
101. Stolk RP, Lamberts SWJ, de Jong FH, Pols HAP, Groebbe DE. Gender difference in the association between cortisol and insulin sensitivity. J Endocrinol 1996; 149: 313-318.
102. Filipowsky J, Ducimetière P, Eschwege E, Richard JL, Rosselin G, Claude JR. The relationship between blood pressure, with glucose, insulin, heart rate, free fatty acids and plasma cortisol levels according to degree of obesity in middle-aged men. J Hypertens 1996; 14: 229-235.
103. Walker BR, Phillips DI, Noon JP, Panarelli M, Andrew R, Edwards HV et al. Increased glucocorticoid activity in men with cardiovascular risk factors. Hypertension 1998; 31: 891-895.
104. Ward AM, Fall CH, Stein CE, Kumaran K, Veena SR, Wood PJ et al. Cortisol and the metabolic syndrome in South Asians. Clin Endocrinol (Oxf) 2003; 58: 500-505.
105. Vicennati V, Pasquali R. Abnormalities of the hypothalamic-pituitary- adrenal axis in women with the abdominal obesity and relationship with insulin resistance: evidence for a central and peripheral alteration. J Clin Endocrinol Metab 2000; 84: 416-422.
106. Karlamangla AS, Singer BH, Seeman TE. Reduction of allostatic load in older adults is associated with lower all-cause mortality: MacArthur studies of successful aging. Psychosm Med 2006; 68: 500-507.
107. Brunner EJ, Hemingway H, Walker BR, Page M, Clarke P, Juneja M et al. Adrenocortical, autonomic and inflammatory cause of the metabolic syndrome. Nested case-control study. Circulation 2002; 106: 2659-2665.
108. Smith GD, Ben-Shlomo Y, Beswick A, Yarnell J, Lightman S, Elwood P. Cortisol, testosterone, and coronary heat disease. Prospective evidence from the Caerphilly Study. Circulation 2005; 112: 332-340.
109. Lac F, Berthon P. Changes in cortisol and testosterone levels and the T/C ratio during an endurance competition and recovery. J Sports Med Phys Fitness 2000; 40: 139-144.
110. Filare E, Benain X, Sagnol M, Lac G. Preliminary results on mood state, salivary testosterone:cortisol ratio and team performance in a professional soccer team. Eur J Appl Physiol 2001; 86: 179-184.
111. Alevizaki M, Cimponeriu A, Lekakis J, Papamichael C, Chrousos GP. High anticipatory stress plasma cortisol levels and sensitivity to glucocorticoids predict severity of coronary artery disease in subjects undergoing coronary angiography. Metabolism 2007; 56: 222-226.
112. Güder G, Bauersachs J, Frantz S, Weismann D, Allolio B, Ertl G et al. Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure. Circulation 2007; 115: 1754-1761.
113. Lin RCY, Wang XL, Morris BJ. Association of coronary artery disease with glucocorticoid receptor N363S variant. Hypertension 2003; 41: 104-407.
114. Hu FCW, von Eckardstein A. Androgens and coronary artery disease. Endocr Rev 2003; 24: 183-217.
115. Kapoor D, Malkin CJ, Channer KS, Jones TH. Androgens, insulin resistance and vascular diseases in men. Clin Endocrinol (Oxf) 2005; 63: 239-250.
116. Ding EL, Song Y, Malik VS, Liu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes. A systematic review and meta-analysis. JAMA 2006; 295: 1288-1299.
117. Hergenc G, Schulte H, Assmann G, von Eckardstein A. Associations of obesity markers, insulin, and sex hormones with HDL-cholesterol levels in Turkish and German individuals. Atherosclerosis 1999; 145: 147-156.
118. Tsai EC, Boyko EJ, Leonetti DL, Fujimto WY. Low serum testosterone levels as a predictor of increased visceral fat in Japanese-American men. Int J Obes 1996; 24: 485-491.
119. Simon D, Charles MA, Nahoul K, Orssaud G, Kremski J, Hully V et al. Association between plasma total testosterone and cardiovascular risk factors in healthy adult men: the TELECOM study. J Clin Endocrinol Metab 1997; 92: 682-685.
120. Muller M, Grobbee DE, den Tonkelaar I, Lamberts SW, van der Schouw YT. Endogenous sex hormones and metabolic syndrome in aging men. J Clin Endocrinol Metab 2005; 90: 2618-2623.
121. Goodman-Gruen D, Barrett-Connor E. Sex difference in the association of endogenous sex hormone levels and glucose tolerance status in older men and women. Diabetes Care 2000; 23: 912-918.
122. Malkin CJ, Pugh PJ, Jones TH, Channer KS. Testosterone for secondary prevention in men with ischaemic heart disease. Quat J Med 2003; 96: 521-529.
123. Wang C, Swerdloff RS, Iranmanesh A, Dobs A, Snyder PJ, Cunningham G et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. Testosterone gel study group. J Clin Endocrinol Metab 2000; 85: 2839-2853.
124. Marin P, Holmang S, Jonsson L, Sjostrom L, Kvist H, Holm G et al. The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. Int J Obes 1992; 16: 991-997.
125. Buchter D, Behre HM, Kliesch S, Chirazi A, Nieschlag E, Assmann G et al. Effect of testosterone suppression in young men by the gonadotropin releasing hormone antagonist cetrorelix on plasma lipids, lipolytic enzymes, lipid transfer proteins, insulin, and leptin. Exp Clin Endocr Diabetes 1999; 107: 522-529.
126. Lindstedt G, Lundberg P, Lapidus L, Lundgren H, Bengtsson C, Bjorntorp P. Low sex hormone binding globulin concentration as an independent risk factor for development of NIDDM: 12 yr follow-up of population study of women in Gotemburg. Diabetes 1991; 40: 123-128.
127. Gambineri A, Pelusi C, Vicennati V, Pagotto U, Pasquali R. Obesity and the polycystic ovary syndrome. Int J Obes 2002; 26: 883-896.
128. Pasquali R, Gambineri A. Role of changes in dietary habits in polycystic ovary syndrome. Reprod Biomed Online 2004; 8: 431-439.
129. De Leo V, la Marca A, Petraglia F. Insulin-lowering agents in the management of polycystic ovary syndrome. Endocr Rev 2003; 24: 633-667.
130. Holmang A, Larsson BM, Brzezinska Z, Bjorntorp P. the effects of short term testosterone exposure on insulin sensitivity in female rats. Am J Physiol 1992; 262: E851-E855.
131. Nilsson C, Niklasson M, Erikson E, Bjorntorp P, Holmag A. Imprinting of females offspring with testosterone results in insulin resistance and changes in body fat distribution at adult age in rats. J Clin Invest 1998; 101: 74-78.
132. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanisms and implications for pathogenesis. Endocr Rev 1997; 18: 774-800.
133. Gambineri A, Patton L, Vaccina A, Cacciari M, Morselli-Labate AM, Cavazza C et al. Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study. J Clin Endocrinol Metab 2006; 91: 3970-3980.
134. Legro RS. Diabetes prevalence and risk factors in polycystic ovary syndrome. Curr Opin Endocrinol Diab 2002; 9: 451-458.
135. Gambineri A, Pelusi C, Manicardi E, Vicennati V, Cacciari M, Morselli-Labate AM et al. Glucose intolerance in a large cohort of Mediterranean women with polycystic ovary syndrome. Phenotype and associated factors. Diabetes 2004; 53: 2353-2358.
136. Legro RS. Polycystic ovary syndrome and cardiovascular disease: a premature association? Endocr Rev 2003; 24: 302-312.
137. Shaw LJ, Bairey Merz CN, Azziz R, Stanczyk FZ, Sopko G, Braunstein GD et al. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health - National Heart, Lung, and Blood Institute sponsored Women's Ischemia Syndrome Evaluation. J Clin Endocrinol Metab 2008; 93: 1276-1284.
138. Battett-Connor EL, Goodman-Gruen D. Prospective study of endogenous sex hormones and fatal cardiovascular disease in postmenopausal women. Br Med J 1995; 311: 1193-1196.
139. Ding EL, Song Y, Manson JE, Rifai N, Buring JE, Liu S. Plasma sex steroid hormones and risk of developing type 2 diabetes in women: a prospective study. Diabetologia 2007; 50: 2076-2084.